Clinical Studies with Anticoagulants to Improve Survival in Cancer Patients

Cancer is linked with hypercoagulability and risk of thrombosis and this close association was recognized by Armand Trousseau in 1865. The relation between cancer and blood coagulation is reciprocal: cancer induces a hypercoagulable state and predisposes to thrombosis and activation of platelets, blood coagulation and fibrinolysis interfere with tumor cell biology, tumor growth, angiogenesis and metastatic process. In the present article, we analyze the clinical trials which assessed the influence of anticoagulant treatment on the survival of patients with cancer. The available data show that low-molecular-weight heparins (LMWHs) tend to be more effective and safer than vitamin K antagonists (VKA) in improving survival in patients with cancer. The beneficial effect of anticoagulation with either LMWHs or VKA is not universal for all patients with cancer. There are some histological types of cancers which, at early stages, appear to be more sensitive than others to the effect of anticoagulant treatment. The available clinical trials, although limited, are encouraging for the beneficial effect of anticoagulant treatment on the survival of cancer patients. More clinical trials are needed, targeting groups of patients homogenous regarding the type of cancer, the stage of the disease and life expectancy. The forthcoming clinical trials have to address some issues regarding the optimal dose, the timing and the duration of treatment with LMWH in relation to chemotherapy or other anticancer therapies.

[1]  H. Büller,et al.  The Effects of Vitamin K-antagonists on Survival of Patients with Malignancy: A Systematic Analysis , 2001, Thrombosis and Haemostasis.

[2]  P. Prandoni,et al.  Warfarin versus low-molecular-weight heparin therapy in cancer patients. , 2005, The oncologist.

[3]  A. Unal,et al.  A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer , 2004, Journal of thrombosis and haemostasis : JTH.

[4]  Elie A Akl,et al.  Anticoagulation in patients with cancer: an overview of reviews. , 2008, Polskie Archiwum Medycyny Wewnetrznej.

[5]  E. Akl,et al.  Oral anticoagulation for prolonging survival in patients with cancer. , 2007, The Cochrane database of systematic reviews.

[6]  L. Borsig.  Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. , 2007, Seminars in thrombosis and hemostasis.

[7]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[8]  R. Bell.  VITAMIN K AND CHEMICAL CARCINOGENEIS , 1978, The Lancet.

[9]  A. Kakkar,et al.  Perioperative heparin-therapy inhibits late death from metastatic cancer. , 1995, International journal of oncology.

[10]  R. Henschler,et al.  The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo , 2006, Thrombosis and Haemostasis.

[11]  K. Propert,et al.  A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Lemarié,et al.  Subcutaneous heparin treatment increases survival in small cell lung cancer , 1994, Cancer.

[13]  Michael Thomas,et al.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Susanne M. Smorenburg,et al.  The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[16]  M. Gilbert,et al.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial , 2008, Cancer Chemotherapy and Pharmacology.

[17]  J. Folkman,et al.  Control of angiogenesis by heparin and other sulfated polysaccharides. , 1992, Advances in experimental medicine and biology.

[18]  V. Egilsson.  CANCER AND VITAMIN K , 1977, The Lancet.

[19]  W. Henderson,et al.  Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75 , 1984, Cancer.

[20]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.

[21]  A. Khorana,et al.  A meta-analysis of anticoagulants as cancer treatment: Impact on survival and bleeding complications , 2007 .

[22]  A. Kakkar,et al.  Can low-molecular-weight heparins improve outcome in patients with cancer? , 2002, Cancer treatment reviews.

[23]  J. Herndon,et al.  Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Akl,et al.  Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review , 2008, Journal of experimental & clinical cancer research : CR.

[25]  P. Novotny,et al.  Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. , 2007, Mayo Clinic proceedings.

[26]  J. Dipalma,et al.  The interaction of vitamins with cancer chemotherapy , 1979, CA: a cancer journal for clinicians.

[27]  B. Yalcin,et al.  Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer , 2007, Journal of surgical oncology.

[28]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Gaetano,et al.  WARFARIN ENANTIOMERS, ANTICOAGULATION, AND EXPERIMENTAL TUMOUR METASTASIS , 1978, The Lancet.

[30]  M. Rodger,et al.  The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials , 2007, Journal of thrombosis and haemostasis : JTH.

[31]  L. Daly.  The first international urokinase/warfarin trial in colorectal cancer , 2005, Clinical & Experimental Metastasis.

[32]  W. Henderson,et al.  Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. , 1981, JAMA.

[33]  S. Mousa.  Anticoagulants in thrombosis and cancer: the missing link , 2002, Expert review of anticancer therapy.

[34]  A. Falanga.  The effect of anticoagulant drugs on cancer , 2004, Current opinion in pulmonary medicine.

[35]  C. Robinson-Cohen,et al.  The effect of anticoagulants on cancer risk and survival: systematic review. , 2007, Cancer treatment reviews.

[36]  A. Trousseau.  Phlegmasia alba dolens. , 1865 .

[37]  R. Schmid,et al.  Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma , 2007, Thrombosis and Haemostasis.

[38]  G. Hommel,et al.  Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. , 2000, International journal of oncology.

[39]  R. Langer,et al.  Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. , 1983, Science.